Replies to post #2055 on Galectin Therapeutics Inc. (GALT)

[biotech2010]

I converted all of my GALTW to GALT last November, the prices were GALT $4.13 and GALTW $1.88.

My concerns were the length of time for the trials to be completed as well as liquidity of GALTW. I also purchased enough additional GALT to give me more total GALT shares than the prior total of GALTW.

I'm not unhappy that I made the switch as selling a large volume of GALTW right now would be problematic as there is almost no volume being traded. I am unhappy, of oourse, at the share price and would think the sale of shares during Q1 had something to do with it; at least they have stopped that now.

As for increasing the number of CX sites, that won't happen for several reasons, one of which is they would need to add additional researchers and it is too late to do that, it's also very possible that once they have filed the trial protocol with the FDA any changes would delay the study. But ask Traber that question on the blog, it would be a good way to test the process.

[Tesla1]

There is plenty of potential good news for 2016 with the psoriasis, melanoma and FX (Liver Fibrosis) trial. 2016 will definitely be the year for demonstrating efficacy for numerous diseases - IMHO

and the FX and CX trial results (when considered together) could also support accelerated approval - IMHO. If GR-MD-02 can actually reduce portal pressure, that would be a huge breakthrough for the treatment of liver disease.